• $291,900.00
    Market Cap
  • 0.00%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
03/31/2024
03/31/2023
03/31/2022
03/31/2021
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-28,770
-38.03%
-46,422
-86.40%
-341,286
N/A
N/A
N/A
Depreciation and Amortization Expense
N/A
N/A
N/A
N/A
N/A
N/A
0
N/A
Total Operating Expenses
2.1M
+11.14%
1.9M
-70.69%
6.5M
+1,990.83%
309,500
-6.07%
Operating Profit
-2.1M
+11.14%
-1.9M
-70.69%
-6.5M
+1,990.83%
-309,500
-6.07%
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
-266,061
N/A
N/A
N/A
N/A
N/A
79,000
0.00%
Income before Taxes
-2.1M
+11.14%
-1.9M
-70.69%
-6.5M
+1,990.83%
-309,500
+23.55%
Income Taxes
N/A
N/A
-154,524
N/A
N/A
N/A
33,490
-60.68%
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-2.4M
+36.27%
-1.7M
-73.07%
-6.5M
+1,990.83%
-309,500
+23.55%
Net Income from Continuing Operations Applicable to Common
-2.4M
+36.27%
-1.7M
-73.07%
-6.5M
+1,990.83%
-309,500
+23.55%
Basic EPS and Net Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Diluted EPS and Net Income
N/A
N/A
N/A
N/A
N/A
N/A
0.00
N/A
Basic Weighted Average Shares
N/A
N/A
N/A
N/A
N/A
N/A
442.4M
+274.68%
Diluted Weighted Average Shares
N/A
N/A
N/A
N/A
N/A
N/A
442.4M
+274.68%
Balance Sheet
Cash and Cash Equivalents
2,654
-70.15%
8,890
-86.07%
63,816
N/A
0
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
2,654
-70.15%
8,890
-86.07%
63,816
N/A
0
N/A
Total Current Assets
3,663
-98.46%
237,184
+85.36%
127,961
+901.81%
12,773
-16.37%
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Assets
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Assets
3,663
-99.97%
12.4M
+2.05%
12.1M
+94,849.98%
12,773
-16.37%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
145,603
-89.71%
1.4M
+761.49%
164,220
N/A
N/A
N/A
Total Current Liabilities
1.3M
-37.32%
2.1M
+77.01%
1.2M
+198.56%
402,494
+18.91%
Total Long-Term Debt
125,000
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Liabilities
1.3M
-41.56%
2.3M
+89.85%
1.2M
+198.56%
402,494
+18.91%
Retained Earnings
-12.4M
+29.65%
-9.6M
+20.15%
-8.0M
+420.51%
-1.5M
+25.33%
Total Stockholders Equity
-1.3M
-113.17%
10.1M
-7.60%
10.9M
+2,903.61%
-389,721
+20.57%
Total Shares Outstanding
1.4B
+71.32%
807.0M
+0.55%
802.6M
+6.41%
754.3M
+480.30%
Cash Flow
Cash from Operating Activities
-1.4M
+39.17%
-1.0M
-2,444.83%
44,344
+188.69%
-50,000
N/A
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
0
+100.00%
-139,799
N/A
N/A
N/A
0
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
1.5M
+21.18%
1.2M
+12,636.55%
-9,669
-119.34%
50,000
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-38.36%
+169.71%
-14.22%
-86.66%
-106.60%
-95.17%
-2,207.09%
+32.22%
Return on Equity
-54.17%
+226.78%
-16.58%
-86.50%
-122.83%
-241.47%
86.82%
-8.86%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
0.003
-97.58%
0.11
+4.69%
0.11
+235.96%
0.03
-29.71%
Cash Ratio
0.002
-52.38%
0.004
-92.09%
0.05
N/A
0.00
N/A
Debt-to-Equity Ratio
-0.20
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
73.87
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow